Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vegzelma vs Avastin in First-Line Metastatic Non-Squamous NSCLC
NCT03676192Phase 3Completed
- Sponsor
- Celltrion
- Start
- Feb 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Celltrion. Primary endpoint: Objective Response Rate. Started Feb 2019; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03676192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676192.